2 active not recruiting, 1 recruiting, 1 suspended, 1 unknown. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Recruiting 1, Suspended 1, Unknown 1 |
Follow Histiocytic Sarcoma: new trials by email Literature Review of Histiocytic Sarcoma trials Research Report on Histiocytic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Cobimetinib - Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma | Phase 2 | Recruiting | Carl Allen | 90 | 2021-04-19 | 2026-10-26 |
| Pembrolizumab in Neoplasms or Lymphomas Pembrolizumab - Lymphoma, Histiocytic Sarcoma | Phase 2 | Suspended | Dana-Farber Cancer Institute | 18 | 2017-12-07 | 2026-08-06 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Lenalidomide for Adult Histiocyte Disorders Lenalidomide - Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 12 | 2015-08-01 | 2026-07-23 |
Histiocytosis, Langerhans-Cell (3) · Erdheim-Chester Disease (2) · Sarcoma (2) · Xanthogranuloma, Juvenile (2) · Central Nervous System Neoplasms (1) · Dendritic Cell Sarcoma, Follicular (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Dermatofibrosarcoma (1) · Ependymoma (1) · Fibrosarcoma (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytic Disorders, Malignant (1) · Histiocytoma, Malignant Fibrous (1)
Hemic and Lymphatic Diseases (5) · Histiocytosis (5) · Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Histiocytic Disorders, Malignant (4) · Histiocytosis, Non-Langerhans-Cell (3) · Lung Diseases (3) · Lung Diseases, Interstitial (3) · Respiratory Tract Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2)
Biopsy (1) · LY3023414 (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · Nuclear Medicine Department, Hospital (1) · Phantoms, Imaging (1) · Radiation Dose Hypofractionation (1) · Specimen Handling (1) · Vemurafenib (1) · X-Rays (1) · cobimetinib (1) · ensartinib (1) · erdafitinib (1) · ivosidenib (1) · larotrectinib (1)
Dana-Farber Cancer Institute (2) · Carl Allen (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · National Cancer Institute (NCI) (1)
United States (4) · Australia (1) · Canada (1) · Poland (1) · Puerto Rico (1)
Eric Jacobsen, MD (2) · Carl E Allen, MD, PhD (1) · Donald W Parsons (1)
PMID 32871584, PMID 33591402, PMID 35353553, PMID 41166674, PMID 42194972, PMID 42686334
U10CA180886 (1)